Such a striking paradigm is provided by the study from Annicotte and colleagues [112] where the presence of the HDAC inhibitor valproic acid is a prerequisite for pioglitazone-mediated anti-metastatic activity in prostate cancer in mice [112]. The gene discussed is HDAC9; the disease is prostate carcinoma.